Blood Grouping Reagents - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The blood grouping reagents market is expected to grow from USD 0.65 billion in 2025 to USD 0.72 billion in 2026 and is forecast to reach USD 1.21 billion by 2031 at 11.12% CAGR over 2026-2031. This report is Segmented by Product Type (Serological Reagents, Molecular Reagents, and Others), Technology (Manual Testing, and Others), Test Type (Blood Typing, Blood Grouping and Phenotyping, and Others), End-User (Hospitals, Blood Banks, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Blood Grouping Reagents Market Trends and Insights

Rising Demand for Safe Blood Transfusion Workflows

The blood grouping reagents market continues to gain support from the constant need for safe transfusion workflows in hospitals and blood services. The United States required nearly 29,000 units of red blood cells every day and transfused nearly 16 million blood components annually, which shows how large the testing base remains even before more advanced compatibility work is considered.The care mix is also shifting, because oncology and cardiovascular procedures now account for a larger share of transfusion demand in advanced health systems, and these patients often return for repeated testing over time. This matters for the blood grouping reagents market because patient blood management programs reduce unnecessary transfusions, but they also increase the clinical importance of each approved transfusion event and each test result. Comparative 2025 research showed sensitivity gaps of up to 19 percentage points between reagent red blood cell brands on the same platform, which is pushing buyers to prioritize published performance evidence instead of only purchase price.

Expansion of Automated Blood Typing and High-Throughput Immunohematology Platforms

The blood grouping reagents market is also being lifted by the spread of automated immunohematology systems in high-volume laboratories. Automated platforms use proprietary cartridges, defined reagent suspensions, and built-in controls, so they create steady consumable demand that manual tube methods do not reproduce. QuidelOrtho received FDA clearance in October 2025 for its Micro Typing Systems DAT Card on the ORTHO VISION platform, which expanded the company’s gel-based direct antiglobulin testing offering and strengthened its installed system proposition.Bio-Rad launched the IH-500 NEXT system in May 2025 with a 6-axis robotic arm and 7 day on-board reagent stability, targeting blood banks that need higher throughput and fewer manual steps. These placements matter in the blood grouping reagents market because analyzer contracts are often paired with multi-year reagent commitments, which raise repeat revenue visibility and make account switching less likely.

High Validation Burden for New Reagent Lots and Methods

The blood grouping reagents market faces a meaningful constraint from the validation burden attached to biologics-grade and regulated transfusion products. In the United States, blood grouping reagents must meet potency, specificity, and avidity requirements under 21 CFR Part 660, which makes development and method extension more demanding than in many routine diagnostics categories. The FDA also approved a Biologics License Application supplement for Immucor in August 2025 with explicit language that placed responsibility on users to validate methods beyond the manual tube procedure described in the insert. This slows the pace of change in the blood grouping reagents market because every new lot, method, or workflow extension can add documentation, staff time, and audit exposure. The result is a competitive advantage for larger manufacturers that have established quality systems and enough installed base to absorb compliance costs over a wider revenue pool.

Other drivers and restraints analyzed in the detailed report include:

• Increasing Organ Transplant and Prenatal Screening Volumes
• Growth in Rare Blood Type Identification and Extended Phenotyping Needs
• Cold Chain Dependence and Shelf-Life Losses in Distribution

Segment Analysis

Serological reagents commanded 58.92% of the blood grouping reagents market in 2025, reflecting their central role in ABO, Rh, and crossmatch protocols across hospitals, blood banks, and clinical laboratories. Their leadership remains durable because serology is built into standard operating procedures, staff training, and daily transfusion practice in most formal blood systems. The blood grouping reagents market continues to depend on these products for routine pre-transfusion and donor testing, which gives the segment a broad installed base that is difficult to replace quickly. Control reagents also maintain steady demand because validated quality assurance remains essential for every approved workflow and every serious laboratory environment.

Molecular reagents are expected to be the fastest-growing product type at 12.84% CAGR through 2031, showing where the blood grouping reagents industry is moving as case complexity rises. The Journal of Translational Medicine study on Del allele detection also supports the value of DNA-based typing where serology can miss clinically meaningful donor variation. Even so, the blood grouping reagents market is not moving toward a simple substitution pattern, because molecular products are being added first in reference, transplant, and chronically transfused patient workflows rather than replacing all routine serological use. The result is a mixed product structure in which serological reagents keep the volume base, while molecular reagents account for an increasing share of high-value work inside the blood grouping reagents industry.

Manual testing held 51.34% share in 2025, which shows that the blood grouping reagents market still rests on tube agglutination and other conventional techniques in a large part of the global installed base. Manual methods remain common where laboratory throughput is low, service support is limited, or analyzer investment is hard to justify. They also remain useful in facilities that want operational flexibility and simple reagent-only protocols without dependence on proprietary instruments. This leaves manual workflows with a meaningful role in the blood grouping reagents market, especially in emerging settings and smaller hospital laboratories. The segment therefore keeps scale even while newer systems take more share in centralized sites.

Automated testing is forecasted to grow at 13.21% CAGR through 2031, making it the fastest-growing technology in the blood grouping reagents market. Automation is attractive in higher-volume blood banks because it reduces manual handling, supports standardization, and helps address technologist shortages. Other technology formats, especially gel card and intermediate automation platforms, still hold a useful middle position because they bridge the gap between manual workflows and full analyzer dependence.

Complete Report Scope:

• By Product Type
  • Serological Reagents
  • Molecular Reagents
  • Blood Grouping Kits
  • Control Reagents
• By Technology
  • Manual Testing
  • Automated Testing
  • PCR-Based and Microarray Techniques
  • Other Technologies
• By Test Type
  • Blood Typing
  • Blood Grouping and Phenotyping
  • Antibody Screening
  • Cross-Matching Tests
  • Other Test Types
• By End-User
  • Hospitals
  • Blood Banks
  • Clinical and Diagnostic Laboratories
  • Other End-Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.72% of the blood grouping reagents market size in 2025, making it the largest regional contributor. The region benefits from a broad hospital blood bank network, strong transfusion volumes, and a strict regulatory framework that supports product quality and premium positioning. The United States alone required nearly 29,000 units of red blood cells each day and transfused nearly 16 million blood components annually, which gives suppliers a large and recurring installed testing base. The FDA licensing framework under 21 CFR Part 660 also raises the entry threshold for new participants and favors companies that can manage extensive validation and post-approval obligations.

Europe remains one of the most established areas in the blood grouping reagents market because hospital consolidation, formal blood banking infrastructure, and advanced immunohematology practice are already well developed across major countries. Germany, the United Kingdom, and France anchor demand through mature transfusion systems and early use of gel and automation-based workflows. Italy and Spain provide steady secondary volume, while parts of Central and Eastern Europe offer room for adoption as healthcare systems modernize. The Middle East and Africa show a split picture, with GCC countries moving toward more modern blood banking standards while many Sub-Saharan markets still face cold chain and workforce constraints that limit the usable reagent range.

Asia-Pacific is projected to grow at 14.25% CAGR through 2031, making it the fastest-growing region in the blood grouping reagents market. The region is gaining from expanding blood banking capacity, a larger formal donation base, and stronger institutional attention to standardized quality in transfusion services. Growth is especially meaningful in large countries where hospital capacity, donor infrastructure, and automation adoption are all rising from a lower base than in North America and Western Europe. Japan and South Korea contribute mature demand with high automation intensity, while China and India provide scale and system expansion that can lift total reagent consumption over the forecast period. South America remains a longer-cycle opportunity in the blood grouping reagents market, with Brazil and Argentina leading regional demand as healthcare formalization and quality expectations improve across major urban centers.

List of Companies Covered in this Report:

• Abbott Laboratories
• Atlas Medical
• BAG Diagnostics GmbH
• Beckton Dickinson
• Beckton Dickinson
• Bio-Rad Laboratories
• Danaher
• DIAGAST SAS
• Roche
• Grifols
• Immucor
• Lorne Laboratories
• Merck
• QuidelOrtho
• Quotient Limited
• Rapid Labs Limited
• Siemens Healthineers
• Sysmex
• Thermo Fisher Scientific
• Tulip Diagnostics (P) Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support